SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
wangwang2168
Lv3
380 积分
2022-09-19 加入
最近求助
最近应助
互助留言
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
6个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
6个月前
已完结
First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer
6个月前
已完结
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
8个月前
已完结
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
8个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
8个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
8个月前
已完结
Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1
10个月前
已关闭
Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1
10个月前
已完结
[Report of cancer epidemiology in China, 2015]
1年前
已完结
没有进行任何应助
没有进行任何互助留言
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论